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Corrigendum
Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-
Cruz IM. Targeting nicotine addiction: the possibility of a 
therapeutic vaccine. Drug Des Devel Ther. 2011;5:211–224.
The following sections are direct quotes from Cerny and Cerny 
(Hum Vaccin. 2009;5(4):200–205).
  • The second, third, and fourth sentences of the abstract, as 
well as the last paragraph of the abstract, except for the 
second sentence (pp. 211)
  • ‘Vaccines against nicotine’ (pp. 217)
  • The first two paragraphs in ‘Vaccines against nicotine under 
evaluation in clinical trials’ (pp. 218) with the exception of 
the last sentence in the second paragraph
  • ‘Cytos AG, Schlieren Switzerland’ (pp. 218)
  • ‘Phase II study of vaccine NIB002’ (pp. 218)
  • ‘Celtic pharma holdings LP’ (pp. 219) with the exception 
of the third-to-last and fourth-to-last sentences
  • ‘Nabi Inc’ (pp. 220) with the exception of the last two 
sentences
  • ‘Chilka Ltd and other competitors developing nicotine 
vaccines’ (pp. 220)
  • ‘Further developments to expect’ (pp. 220)